Patient is concurrently receiving chemotherapy, biologics, immunotherapy for cancer treatment; systemic anti-cancer treatment or investigational treatment
Patient is concurrently using other anti-cancer therapy.
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting study treatment with sonidegib
Patient is concurrently using other approved or investigational antineoplastic agent
Patient is concurrently using other approved or investigational antineoplastic agent
Concurrently using fibrin sealants or other anastomosis care devices
Patient is concurrently using other approved or investigational antineoplastic agent
Patient is concurrently using other approved or investigational antineoplastic agents
Patient is concurrently using other anti-cancer therapy.
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting LDE225
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy, or radiotherapy) concurrently or within 2 weeks of starting treatment
Patient who is concurrently using any other approved or investigational anti-neoplastic agent
Patient is concurrently using other approved or investigational antineoplastic agent
Patient is concurrently using other approved or investigational antineoplastic agents
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting treatment with LDE225
